technical analysis

The stock appears to have lost its way.
Chart indicate it will drift lower.
The weekly chart looks constructive but the daily chart is not robust.
Juno Therapeutics' chart, and fortune, is on the rise.
This stock could be headed for $120.
Meanwhile, I continue to hold long-term favorites like Energy Recovery, TPI Composites and Aratana.
The technical signs indicate the stock's price and volume are going up without a dip.
There is not enough evidence to say the Fed can swing this.
it looks like the selloff is largely over and the uptrend can resume.
Shares of the luxury builder are still weak and are now testing support.

Columnist Conversations

No big surprise here;  company never put up a profitable quarter from operations. Says it filed in order ...
Costco is working on its fourth straight decline.  Today the stock is taking out the initial September an...
People old enough to be on Medicare, but not yet collecting social security payments in 2016, may be in for an...
Reuters ran a story this morning that National Amusement, Sumner and Shari Redstone's holding company, has ask...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.